卵巢癌是全球女性中第8种最致命的常见癌症。几乎所有的卵巢癌患者都会经历化疗耐药,复发,细胞减灭术和铂类化疗后预后不良。化疗耐药的癌细胞具有肿瘤干细胞蛋白(CSCs)CD44+/CD24-的特征性表达,RAD6和DDB2。CD44+/CD24-的表达增加,RAD6和DDB2的降低被认为与化学抗性有关,复发,和疾病的不良预后。因此,本研究的目的是分析CD44+/CD24-,RAD6和DDB2与卵巢癌化疗耐药。
■这项研究是在CiptoMangunkusumo妇产科和病理科进行的64名患者的前瞻性队列研究,分为两组(每组32名患者),Tarakan,Dharmais,和Fatmawati医院.所有疑似卵巢癌患者均接受了细胞减灭术和组织病理学检查。进行了六个系列的化疗,然后进行了六个月的观察。在观察之后,我们使用RECIST标准(实体瘤的反应标准)确定治疗的反应,然后将结果分为化学耐药组或化学敏感组.然后进行流式细胞术血液测试以检查CD44/CD24-的表达,RAD6和DDB2。
■CD44+/CD24-,和RAD6(p<0.05)水平与卵巢癌化疗耐药有关。Logistic回归检验显示CD44+/CD24-是较好的标记物。
■这些结果表明CD44+/CD24和RAD6的表达与卵巢癌化疗耐药显著相关,CD44+/CD24-是预测卵巢癌化疗耐药的较好指标。
UNASSIGNED: Ovarian cancer is the 8th deadliest common cancer in women around the world. Almost all ovarian cancer patients would experience chemoresistance, recurrence, and poor prognosis after cytoreductive surgery and platinum-based chemotherapy. Chemoresistant cancer cells have characteristic expressions of cancer stem cell proteins (CSCs) CD44+/CD24-, RAD6 and DDB2. The increased expression of CD44+/CD24-, RAD6, and decreased DDB2 are believed to be associated with chemoresistance, recurrence, and poor prognosis of the disease. Thus, this study\'s objective is to analyze the correlation between the expression of CD44+/CD24-, RAD6 and DDB2 with ovarian cancer chemoresistance.
UNASSIGNED: This study was conducted with a prospective cohort of 64 patients who is divided into two groups (32 patients in each group) at the Obstetrics-gynecology and pathology department of Cipto Mangunkusumo, Tarakan, Dharmais, and Fatmawati Hospital. All suspected ovarian cancer patients underwent cytoreductive debulking and histopathological examination. Chemotherapy was given for six series followed by six months of observation. After the observation, we determined the therapy\'s response with the RECIST Criteria (Response Criteria in Solid Tumors) and then classified the results into chemoresistant or chemosensitive groups. Flow cytometry blood tests were then performed to examine the expression of CD44+/CD24-, RAD6 and DDB2.
UNASSIGNED: There was a significant relationship between increased levels of CD44+/CD24-, and RAD6 (p < 0.05) levels with the chemoresistance of ovarian cancer. The logistic regression test showed that the CD44+/CD24- was better marker.
UNASSIGNED: These results indicate that CD44+/CD24 and RAD6 expressions are significantly associated with ovarian cancer chemoresistance, and CD44+/CD24- is the better marker to predict ovarian cancer chemoresistance.